U.S. Infrastructure Stock News

NasdaqGM:SITM
NasdaqGM:SITMSemiconductor

Why SiTime (SITM) Is Up 25.4% After Profit Swing And Higher Q3 Revenue Guidance - And What's Next

In the past quarter, SiTime Corporation reported second-quarter 2026 sales of US$157.43 million, moving from a loss to a net income of US$18.16 million, and issued third-quarter revenue guidance of US$285 million to US$295 million. Beyond the headline profit turnaround, the sharp year-on-year increase in earnings per share highlights how SiTime’s higher sales are now translating into meaningful profitability. Next, we’ll consider how this swing back to profit and stronger revenue outlook may...
NYSE:IVZ
NYSE:IVZCapital Markets

Will Earnings Rebound And Steady Payouts Change Invesco's (IVZ) Capital Allocation Narrative?

Invesco Ltd. has reported past second-quarter 2026 results showing revenue of US$1,825.6 million and net income of US$382.3 million, alongside maintaining a US$0.215 common dividend, a US$14.75 preferred dividend, and continuing share repurchases under its long-running buyback program. The sharp year-on-year swing from a loss per share to earnings, combined with ongoing cash returns through dividends and buybacks, highlights how Invesco is pairing improved profitability with continued...
NasdaqGS:DOX
NasdaqGS:DOXIT

Amdocs (DOX) Following Mixed Results And Lowered Outlook Still Looks Undervalued

Amdocs (DOX) is in focus after a mixed earnings update, lowered full year profit guidance, and a new quarterly outlook that together highlight margin pressure despite ongoing revenue growth and recent capital returns. See our latest analysis for Amdocs. Amdocs' share price has climbed over the past month, with a 30 day share price return of 12.87%. However, this comes after a year to date share price decline of 26.91% and a 1 year total shareholder return decline of 29.96%. This suggests...
NasdaqGS:FTDR
NasdaqGS:FTDRConsumer Services

Is Frontdoor (FTDR) Fully Valued After Its Q2 2026 Results And Guidance Raise?

Frontdoor (FTDR) recently reported second quarter 2026 results, along with updated guidance that may influence how investors reassess the stock’s risk and return trade off. See our latest analysis for Frontdoor. Frontdoor’s share price has pulled back 7.6% over the last trading day to $83.91, although a 32.2% 3 month share price return and 49.7% 1 year total shareholder return suggest momentum has recently been building as earnings, guidance and buybacks stay in focus. If Frontdoor’s move has...
NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update

Why Monte Rosa Therapeutics Stock Is Back In Focus After Q2 Results Monte Rosa Therapeutics (GLUE) is drawing attention after reporting a second quarter net loss of US$43.4 million and basic loss per share of US$0.43, compared with smaller losses a year earlier. See our latest analysis for Monte Rosa Therapeutics. The latest results appear to have shifted sentiment around Monte Rosa Therapeutics, with the share price at US$15.82 after a 1 month share price return that is down 31.34%, even...
NYSE:TTC
NYSE:TTCMachinery

Should Slowing Revenue, EPS Growth And Returns Require Action From Toro (TTC) Investors?

Recently released analysis on The Toro Company highlighted that its revenue and earnings per share have been growing more slowly than those of industrial peers, alongside an erosion in returns on capital that points to aging profit centers. This weaker financial momentum raises fresh questions about the durability of Toro’s long-standing profit engines at a time when investors are closely comparing performance across the sector. Now, we’ll explore how Toro’s slower revenue and earnings...
NYSE:IVZ
NYSE:IVZCapital Markets

Invesco Stock And 2 Alternative Asset Managers Worth A Closer Look

AI infrastructure, energy security worries and policy shocks around healthcare are pulling capital in very different directions right now. Alternative asset managers sit close to these currents, often deciding where trillions move next. That creates both openings and tripwires for your portfolio. This article walks through 3 stocks from the Alternative Asset Managers screener that appear positively exposed to the recent news and explains why each one merits a closer look. The 3 stocks covered...
NasdaqGS:UPWK
NasdaqGS:UPWKProfessional Services

What Upwork (UPWK)'s Softer 2026 Outlook and New AI MCP Integration Mean For Shareholders

In August 2026, Upwork reported second‑quarter 2026 results showing slightly lower year‑on‑year revenue of US$191.66 million and reduced net income, issued softer guidance calling for US$176 million to US$184 million in third‑quarter revenue and US$730 million to US$750 million for full‑year 2026, completed a share repurchase tranche, and launched its new AI‑integrated Upwork MCP server at no extra cost to users. The combination of cautious revenue and earnings guidance alongside the rollout...
NYSE:HL
NYSE:HLMetals and Mining

Why Hecla Mining (HL) Is Up 21.6% After Q2 Earnings Beat And High-Grade Exploration Results

Hecla Mining Company has already reported its second-quarter 2026 results, with sales rising to US$333.85 million and net income reaching US$117.88 million, while also updating production guidance and maintaining quarterly dividends on both common and preferred stock. Alongside these earnings, Hecla released drilling results that extended high-grade silver mineralization at Keno Hill and uncovered new high-grade veins at Midas, underscoring how exploration progress is reshaping the company’s...
OTCPK:FMCC
OTCPK:FMCCDiversified Financial

Federal Home Loan Mortgage (FMCC) Could Be 64% Undervalued On Stronger 2026 Earnings

Earnings jump puts Federal Home Loan Mortgage stock back in focus Federal Home Loan Mortgage (FMCC) drew fresh attention after reporting Q2 2026 net income of US$3,838 million, compared with US$2,387 million a year earlier, alongside stronger first half figures. The company also reported net income of US$7,396 million for the first six months of 2026, compared with US$5,181 million in the same period of 2025, which gives investors updated insight into its recent profitability. See our latest...
NasdaqGS:RPRX
NasdaqGS:RPRXPharmaceuticals

How Royalty Pharma’s Stronger H1 2026 Earnings and New Academic Focus At Royalty Pharma (RPRX) Has Changed Its Investment Story

Royalty Pharma plc has reported past second-quarter 2026 results showing revenue of US$674.14 million versus US$578.67 million a year earlier, with quarterly net income easing to US$17.88 million and diluted EPS from continuing operations at US$0.04. Over the first half of 2026, revenue rose to US$1.30 billion and net income to US$312.57 million, while the company also strengthened its academic and innovation ties by appointing Greg Raskin, M.D. as Senior Vice President, Head of Academic...
NYSE:IP
NYSE:IPPackaging

Is International Paper (IP) Undervalued As Quarterly Sales Fell And It Posted A Loss?

What International Paper’s latest earnings mean for investors International Paper (IP) recently released second quarter 2026 results that showed lower sales compared with a year earlier and a net loss for the period. This earnings swing is now central to how investors view the stock. For the quarter ended June 30, 2026, International Paper reported sales of US$6,004 million compared with US$6,142 million a year earlier. The company moved from net income of US$75 million in the prior year...
NasdaqGS:AEIS
NasdaqGS:AEISElectronic

Advanced Energy Industries (AEIS) Moved, What Is Drawing Attention Now?

Advanced Energy Industries (AEIS) has drawn fresh attention after reporting record second quarter 2026 results, with revenue and earnings ahead of its own guidance and a higher full year revenue growth outlook. See our latest analysis for Advanced Energy Industries. At a share price of $314.49, Advanced Energy Industries has had a choppy few months, with the share price return down 7.34% over 90 days but still up 41.67% year to date. Its 1 year total shareholder return of 107.80% and 5 year...
NasdaqGS:LINC
NasdaqGS:LINCConsumer Services

Can Lincoln Educational’s (LINC) Solid Q2 Amid Enrollment Headwinds Reframe Its Risk-Reward Narrative?

In the past week, Lincoln Educational Services Corporation reported second-quarter 2026 results, with sales rising to US$142.56 million and net income to US$1.95 million, and reiterated full-year guidance for revenue of US$590.0 million to US$600.0 million and diluted EPS of US$0.74 to US$0.83. An interesting wrinkle is that this strong revenue and earnings performance came despite acknowledged headwinds in student start growth and conversion rates, as the company continues to invest in new...
NYSE:RVTY
NYSE:RVTYLife Sciences

Taylor Farms Recall Puts Food Safety Stocks On Retail Investors Radar

A salmonella-linked recall at Taylor Farms has pushed food safety from the back room of the supply chain to the front page. When a company producing 40% of salad kits in the US faces questions, attention quickly shifts to the tools and services that help prevent the next incident. This article explores 3 stocks exposed to this news and how their food testing and quality control solutions might matter for your portfolio decisions. The stocks in the list below are just a starting sample, and...
NYSE:AON
NYSE:AONInsurance

Boston Scientific Stock And 2 Low Volatility Picks For A Slower US Economy

With the Trump administration now openly acknowledging weak U.S. economic data and investors on edge about slowing growth, the hunt for calmer corners of the market has intensified. Periods of rising anxiety and possible policy responses can punish fragile balance sheets and reward resilience. This article walks through three low volatility stocks that appear relatively better placed against this backdrop and explains why each one might deserve a closer look right now. The stocks covered...
NasdaqGS:ENSG
NasdaqGS:ENSGHealthcare

Ensign Group (ENSG) Faces New Legal Questions Following Probe Into Its Rich Valuation

Legal investigation raises new questions for Ensign Group stock Kehoe Law Firm, P.C. has opened an investigation into Ensign Group (ENSG) following allegations from short seller Muddy Waters Research about improper practices at roughly 20% of its skilled nursing facilities. The review centers on potential breaches of fiduciary duty and regulatory oversight by certain officers and directors. For investors in Ensign Group stock, the focus now turns to how any legal or reputational fallout might...
NYSE:FICO
NYSE:FICOSoftware

Should Fair Isaac’s Buybacks And Higher Guidance Amid Scoring Competition Require Action From FICO Investors?

In late July 2026, Fair Isaac Corporation reported third-quarter revenue of US$674.19 million and net income of US$237.17 million, alongside higher full-year guidance and confirmation of large-scale share repurchases totaling over US$2.69 billion across two completed buyback programs. Despite strong year-on-year growth in revenue and earnings per share, the results were viewed against concerns about competitive pressures in credit scoring and the long-term implications of lenders...
NYSE:XPRO
NYSE:XPROEnergy Services

Why Expro (XPRO) Is Up 11.8% After Raising 2026 Revenue Guidance Despite Weaker Q2 Results

In late July 2026, Expro Ltd. reported second-quarter 2026 results showing lower sales and earnings year-on-year, while also completing a US$40,000,000 share repurchase program covering 2.2% of its shares. On the same day, Expro raised its full-year 2026 revenue guidance to US$1.65 billion–US$1.70 billion, reflecting contributions from the Enhanced Drilling acquisition and a geographically diverse project pipeline despite ongoing Middle East disruptions and softer expectations for its...
NYSE:SPXC
NYSE:SPXCMachinery

How Investors Are Reacting To SPX Technologies (SPXC) Earnings Beat And Upgraded 2026 Revenue Guidance

In the past quarter, SPX Technologies, Inc. reported second-quarter 2026 sales of US$679 million and net income of US$78.4 million, with both quarterly and first-half earnings per share rising versus the prior year. Alongside these results, SPX Technologies raised its full-year 2026 revenue guidance to a range of US$2.71 billion to US$2.77 billion, signaling stronger-than-previously-expected business momentum. Building on this upgraded full-year revenue outlook, we’ll now examine how the...
NasdaqGS:EYE
NasdaqGS:EYESpecialty Retail

National Vision Holdings (EYE) Could Be 23% Below Fair Value On Premium Product Mix

Recent share price context and business snapshot National Vision Holdings (EYE) has drawn investor interest after recent share price moves, with the stock closing at $22.43. The company sits near a market value of about $1.8b. The optical retailer generates revenue of about $2,021.0m and net income of $46.6m. Its operations span eyeglasses, contact lenses, accessories and eye exams across brands such as America's Best and Eyeglass World. See our latest analysis for National Vision...
NasdaqGM:GHRS
NasdaqGM:GHRSPharmaceuticals

GH Research (GHRS) Looks Pricey Following Wider Losses In Its Latest Earnings Report

GH Research (NasdaqGM:GHRS) drew investor attention after reporting second quarter 2026 results, with a net loss of US$15.15 million and a basic loss per share from continuing operations of US$0.23. See our latest analysis for GH Research. Despite the wider loss just reported, GH Research’s share price has climbed strongly over 2026, with a year to date share price return of 123.04% and a 1 year total shareholder return of 150.25%, signalling strong positive momentum in investor sentiment. If...
NasdaqGS:IDCC
NasdaqGS:IDCCSoftware

InterDigital (IDCC) After Raised 2026 Guidance Is The Stock Still Undervalued

InterDigital earnings and guidance in focus after Q2 report InterDigital (IDCC) reported second quarter 2026 results with lower sales and earnings compared with a year earlier, while at the same time raising its full year revenue and net income guidance. The company posted second quarter sales of $260.17 million versus $300.6 million a year ago. Net income was $116.37 million compared with $180.57 million, with diluted earnings per share from continuing operations at $3.40 versus $5.35. For...
NYSE:QGEN
NYSE:QGENLife Sciences

Is Qiagen (QGEN) Undervalued Following FDA Clearance And Strong Q2 Guidance?

The FDA clearance of Qiagen (QGEN) QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infections, together with the company exceeding its second quarter outlook and reaffirming full year guidance, has sharpened investor focus on the stock. See our latest analysis for Qiagen. The recent QIAstat-Dx blood culture panel clearance and Q2 results appear to have coincided with a sharp shift in sentiment, with a 90 day share price return of 30.12% contrasting with a year to date share price decline...